Revotar Biopharmaceuticals AG

May 18, 2011 12:26 ET

Revotar presents significant final results from 4 weeks Phase II COPD study

HENNIGSDORF, GERMANY--(Marketwire - May 18, 2011) -

Revotar Biopharmaceuticals AG / Revotar presents significant final results from 4 weeks Phase II COPD study . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

BERLIN/Hennigsdorf (Germany), May 18, 2011 - Revotar Biopharmaceuticals AG, a biotech company focusing on the development of small molecule anti- inflammatory drug candidates, today announced the final data (final TLFs) of its Phase II COPD study. The data confirm the already outlined positive top-line results released on March 30, 2011. The primary endpoint IL-8 was met with high statistical significance. "Our recent results confirm the broad and significant anti-inflammatory effect with clear indications on improvement of lung function in COPD patients (GOLD II-III)", emphasized Dr. Martin Poehlchen, CEO of the company.

The company attends the ongoing International Conference of the American Thoracic Society (ATS). The clinical investigator Prof. Helgo Magnussen (Großhansdorf, Germany) and his team present the latest published data[1] of a previous phase IIa study with Bimosiamose (ozone provocation study) in healthy volunteers.

"We will discuss our positive data and the future clinical development with international key opinion leaders at the ATS conference in Denver", said Prof. Wolfgang Meyer-Sabellek, CMO of Revotar.

[1] Kirsten A, Watz H, Kretschmar G, Pedersen F, Bock D, Meyer- Sabellek W, Magnussen H.; Efficacy of the pan-selectin antagonist Bimosiamose on ozone- induced airway inflammation in healthy subjects - A double blind, randomized, placebo-controlled, cross-over clinical trial; Pulm Pharmacol Ther. 2011 Apr 14. [Epub ahead of print]

About COPD

Chronic Obstructive Pulmonary Disease (COPD) comprises several serious conditions affecting the lung. According to the WHO, COPD is affecting more than 210 million people worldwide, of which about 80 million people suffer from moderate to severe forms of the disease. More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally. The WHO predicts that COPD will become the third leading cause of death worldwide by 2030. In 2009, the global COPD market recorded sales of approximately 10 billion US-$.

About Revotar Biopharmaceutical AG

Revotar develops innovative drugs for inflammatory indications such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI) and asthma. Its lead candidate Bimosiamose, a pan-selectin antagonist, has already passed several clinical phase I and phase IIa trials in COPD, asthma and psoriasis with a good safety and efficacy profile in over 300 patients and volunteers. Furthermore, Revotar has two preclinical programs addressing respiratory and other inflammatory diseases.




Contact Address: Dr. Martin Pöhlchen, CEO Revotar Biopharmaceuticals AG Neuendorfstr. 24a D-16761 Hennigsdorf / Germany Phone: 3302-2025010 Fax: 3302-2025030 Email:info@revotar.com www.revotar.com




--- End of Message ---

Revotar Biopharmaceuticals AG Neuendorfstr. 24a Hennigsdorf Germany



Press Release (PDF): http://hugin.info/143207/R/1517022/453457.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Revotar Biopharmaceuticals AG via Thomson Reuters ONE

[HUG#1517022]

Contact Information

  • Contact Address:
    Dr. Martin Pöhlchen
    CEO
    Revotar Biopharmaceuticals
    AG Neuendorfstr. 24a D-16761
    Hennigsdorf / Germany
    Phone: +49-3302-2025010
    Fax: +49-3302-2025030
    Email:info@revotar.com
    www.revotar.com